Search research articles
Contact Us
Filters
Showing results (21-30 of 52) with videos related to
Page
of 6
Sort By:
JCO Precision Oncology
|
June 12, 2024
Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2
Erica S Tsang, Mallika S Dhawan, Romain Pacaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 8, 2022
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Xuyang Song, Robin Kate Kelley, Anis A Khan, et al.
British Journal of Cancer
|
October 8, 2021
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
Robin Kate Kelley, Rebecca Miksad, Irfan Cicin, et al.
Liver Cancer
|
February 28, 2022
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2024
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
Bruno Sangro, Peter R Galle, Robin Kate Kelley, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 2, 2024
<sup>68</sup>Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with <sup>18</sup>F-FDG
Brad Kline, Surekha Yadav, Youngho Seo, et al.
Liver Cancer
|
January 26, 2026
Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis
Stephen Lam Chan, Masatoshi Kudo, Bruno Sangro, et al.
Nature Reviews. Clinical Oncology
|
June 10, 2026
Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement
Josep M Llovet, Ezequiel Mauro, Lorenza Rimassa, et al.
JCO Precision Oncology
|
February 9, 2022
Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype
Apurva Jain, Mitesh J Borad, Robin Kate Kelley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2020
Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Robin Kate Kelley, Tim Meyer, Lorenza Rimassa, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 52) with videos related to
Sort By:
Page
of 6
JCO Precision Oncology
|
June 12, 2024
Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2
Erica S Tsang, Mallika S Dhawan, Romain Pacaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 8, 2022
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Xuyang Song, Robin Kate Kelley, Anis A Khan, et al.
British Journal of Cancer
|
October 8, 2021
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
Robin Kate Kelley, Rebecca Miksad, Irfan Cicin, et al.
Liver Cancer
|
February 28, 2022
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2024
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
Bruno Sangro, Peter R Galle, Robin Kate Kelley, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 2, 2024
<sup>68</sup>Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with <sup>18</sup>F-FDG
Brad Kline, Surekha Yadav, Youngho Seo, et al.
Liver Cancer
|
January 26, 2026
Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis
Stephen Lam Chan, Masatoshi Kudo, Bruno Sangro, et al.
Nature Reviews. Clinical Oncology
|
June 10, 2026
Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement
Josep M Llovet, Ezequiel Mauro, Lorenza Rimassa, et al.
JCO Precision Oncology
|
February 9, 2022
Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype
Apurva Jain, Mitesh J Borad, Robin Kate Kelley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2020
Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Robin Kate Kelley, Tim Meyer, Lorenza Rimassa, et al.
Page
of 6